Although tumor necrosis factor-a (TNF-a) blockade is a very effective therapy for rheumatoid arthritis (RA), not all patients achieve a favorable outcome. The objective of this study was to determine if the common TNF-a variant À308(A) predicts poor response to TNF-a inhibitors in RA patients using meta-analysis. Studies were identified using MEDLINE and EMBASE. Data were extracted based on DAS28 or achieving at least American College of Rheumatology 20 response. A total of nine studies met the inclusion criteria representing a total of 692 RA patients. There was no significant heterogeneity among study effect sizes (P ¼ 0.36). The frequency of the A allele was 22% (119/531) in responders and 37% (60/161) in nonresponders. The odds of having the A allele was lower in responders versus non-responders (odds ratio (OR) ¼ 0.43, 95% confidence intervals (CI): 0.28À0.68, P ¼ 0.000245), irrespective of the TNF-a inhibitor prescribed, indicating that the À308(A) variant predicts poor response to TNF-a inhibitors. The clinical utility of prospectively genotyping for this variant when initiating anti-TNF-a therapy for RA should now be formally assessed.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease resulting in inflammation in articular and extra-articular structures. 1 Although the etiology of RA remains elusive, there is substantive evidence that tumor necrosis factor-a (TNF-a) is a key cytokine in the pathogenesis of RA. The latter plays a pivotal role in stimulating cytokines critical in initiating and perpetuating inflammation in RA. 2 It also activates the endothelium, enhances the expression of adhesion molecules and co-stimulates T-cell activation and antibody production by B cells.
These biologics are of benefit as monotherapy or in combination with disease-modifying drugs.
Despite the marked improvement of symptoms and radiographic retardation of RA with the use of anti-TNF-a agents, randomized controlled trials reveal that only 70% of patients with moderate-to-severe RA achieve a satisfactory response, as defined by an American College of Rheumatology 20 response (ACR20). 4 The response rate for inflammatory arthritis seems to be similar for all the three anti-TNF-a agents presently marketed for RA in North America. 4 Furthermore, the use of these agents has been associated with side effects, some of which may have serious consequences. 5 Given that anti-TNF-a agents are expensive and are potentially associated with serious adverse events, minimizing exposure of these biologics to non-responders will improve their safety, efficacy and pharmaco-economic profile. At present, there are limited clinical and biochemical predictors of response to TNF-a blockade in RA.
Pharmacogenetics has drawn a great deal of attention for its potential to individualize drug therapy. With respect to anti-TNF-a agents in RA, there is a growing body of evidence directed at a single nucleotide polymorphism (SNP) in the human TNF-a gene promoter, the À308 G/A variant. This variant of the TNF-a gene has been selected partly because of its functionality, as this SNP may influence the magnitude of the secretory response of TNF-a. 6 In addition, variants of the À308 SNP are associated with increased susceptibility to and severity of RA. 7 At present, there are a handful of small studies that have set out to examine whether the G to A polymorphism at position À308 in the promoter of the TNFa gene influences clinical response to TNF blockade in patients with moderate-to-severe RA. [8] [9] [10] [11] [12] [13] [14] [15] [16] Owing to the relatively small number of patients exposed to anti-TNF-a agents in all of the pharmacogenetic studies in RA to date, each individual study had insufficient power to conclusively determine if the À308 variant of the TNF-a gene would be helpful in predicting patients that respond poorly to TNF-a blockade. Lee et al. 17 carried out a metaanalysis investigating the association of TNF-a À308 G/A polymorphism with responsiveness to TNF-a-blockers in RA. A total of six studies were included in that analysis, including 240 responders and 70 non-responders, representing a total of 310 RA patients. 17 However, in the 3 years since that report, there have been an additional four studies investigating the association of TNF-a À308 G/A polymorphism with responsiveness to TNF-a-blockers in RA. [13] [14] [15] [16] These recent studies account for an additional 408 RA patients exposed to anti-TNF-a agents, including 306 responders and 102 non-responders. As a result, we set out to carry out a more current and detailed meta-analysis of the effect of TNF-a À308 A/G variant and response to anti-TNF-a therapy in patients with RA.
Results
Pharmacogenetic studies investigating the influence of the TNF-a promoter À308 A/G polymorphism on response to TNF-a inhibitors in RA patients were evaluated. Whereas a total of 11 hits were obtained using our search algorithm, two papers were excluded. One was a meta-analysis with no new original data 17 and the second study pooled results of two diseases, Crohn's disease and RA, which were treated with anti-TNF therapy. 18 As we were unable to extract the data solely for RA patients, this study was excluded.
Characteristics pertinent to the meta-analysis, including genotype frequency of the TNF-a promoter À308 A/G polymorphism between responders and non-responders in RA patients, as well as the corresponding percent response are summarized in Table 1 . The size of the cohorts in each study ranged from a low of 16 10 to a high of 198, 16 with a total of 692 RA patients. Three TNF-a inhibitors were included in the meta-analysis: adalimumab, etanercept and infliximab. Although the raw data was not available in one study, 11 counts were derived from Figure 1 of the metaanalysis carried out by Lee et al.
17
.
The follow-up period ranged from 12 weeks to 25 months. A successful response to anti-TNF-a blockade in moderateto-severe RA was defined as a decrease in DAS X1.2 (preferred outcome) or achieving at least an ACR20. Five of the nine studies used DAS X1.2, three studies used ACR20, whereas one study considered responders to be those who fulfilled either DAS X1.2 or ACR20.
Meta-analysis of the nine studies showed the presence of an A allele significantly decreased response to TNF-a inhibitors in RA patients (Figure 1 ). The frequency of the A allele carrier state was 119/531 (22%) in responders and 60/ 161 (37%) in non-responders ( Figure 1 ). We did not observe significant heterogeneity between studies (Cochrane Q test P ¼ 0.37; I 2 ¼ 8.17%), indicating that the results from all the studies were reasonably consistent with one another. The odds for the A allele carrier state was significantly decreased in responders versus non-responders (odds ratio (OR) ¼ 0.43, 95% confidence interval (CI): 0.28-0.68, P ¼ 0.000245; Figure 1 ). Therefore, carriage of the A allele for the À308 SNP predicted poor response to anti-TNF-a therapy.
To determine the effect of the TNF-a promoter À308 A/G polymorphism on response to TNF-a inhibitors in RA patients solely of Caucasian descent, the meta-analysis was repeated excluding the Korean cohort. 12 Although increased compared with Figure 1 , there was no significant heterogeneity (Cochrane Q test P ¼ 0.27; I 2 ¼ 19.6%) among the Caucasian studies ( Figure 2 ). Again the presence of an A allele was significantly associated with a decreased response to TNF-a inhibitors in RA patients of Caucasian descent ( Figure 2 ). The frequency of the A allele carrier state was 118/ 471 (25%) in responders and 60/151 (40%) in nonresponders ( Figure 2 ). The odds of the A allele carrier state was significantly decreased in responders versus nonresponders (OR ¼ 0.41, 95% CI: 0.25-0.68, P ¼ 0.00045; Figure 2 ). Exclusion of the Korean cohort study 12 did not impact the meta-analysis, as the OR estimated from this study had high variance and only received 1.6% of the total weight in the full meta-analysis. Funnel plots of the ORs from each study against the inverse of their variances were examined with and without the Korean cohort study.
Although there were only nine studies in the meta-analysis, making interpretation difficult, there was no obvious evidence of publication bias (data not shown).
To investigate if RA patients carrying an A allele of the TNF-a À308 G/A polymorphism is associated more strongly with a poor response to a specific TNF-a blocker, studies were grouped and data were analyzed on the basis of the specific TNF-a inhibitor used. In the five studies in which RA patients received infliximab, 172/233 (74%) of patients with a G/G genotype and 55/88 (63%) of patients carrying an A Figure 1 Forest plot of a fixed effects meta-analysis of nine studies evaluating the responsiveness of patients to TNF-a inhibitors by genotype at the TNF-a À308 variant. A random effect model was initially fit, which collapsed to the fixed effect model in the absence of heterogeneity (I 2 ¼ 8.2%). The vertical line in the OR plot is at 1, corresponding to the null hypothesis of no genotype effect. CI, confidence interval; n, number of responders or non-responders carrying the A allele; N, total number of responders or non-responders; OR, odds ratio; TNF-a, tumor necrosis factor-a.
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allele responded to the treatment (Table 2) . Likewise, in studies in which RA patients received etanercept, 190/224 (85%) of patients with a G/G genotype and 47/68 (69%) of patients carrying an A allele responded to the treatment (Table 2) . Similarly, 50/56 (89%) of RA patients with a G/G genotype and 17/23 (74%) of patients carrying an A allele responded to adalimumab treatment ( Table 2 ). All three biologics seem to have similar response rates to TNF-a À308 variants. A subgroup analysis did not show a significant difference in the OR estimates for each inhibitor (Q ¼ 0.98, df ¼ 2, P ¼ 0.61), although the number of studies in each group is low, and is hampered by low overall sample size.
The decrease in DAS28 score in RA patients was subsequently quantified on the basis of the TNF-a À308 A/G polymorphism. The three TNF-a inhibitors were grouped together for analysis purposes. Six of the nine studies quantified the decrease in DAS28 score, which represented 124/179 (69%) of the A allele carriers in RA patients and 483/692 (70%) of the total RA population included in the meta-analysis. There was a significant difference in the decrease in DAS28 score (difference ¼ 1.09, 95% CI: 0.32-1.85, P ¼ 0.00527) for the A allele carrier state compared with the G/G genotype (Figure 3) , using a random effects model. In this meta-analysis of the six studies with change Figure 2 Forest plot of a fixed effects meta-analysis of eight studies with patients of Caucasian descent. A random effects model was initially fit, which collapsed to the fixed effects model in the absence of significant heterogeneity (I 2 ¼ 19.6%). The vertical line in the OR plot is at 1, corresponding to the null hypothesis of no genotype effect. CI, confidence interval; n ¼ number of responders or non-responders carrying the A allele; N, total number of responders or non-responders; OR, odds ratio. Abbreviations: ACR20, American College of Rheumatology 20% improvement criteria; DAS28, disease activity score using 28 joint counts; TNF-á, tumor necrosis factor-a.
in DAS28 scores, there was significant heterogeneity among the studies (I 2 ¼ 92.7%). Visual inspection of the forest plot ( Figure 3 ) revealed that the difference estimates from two studies (11, 14) had much smaller standard errors than the other four studies. We contacted the authors of these two studies, who reconfirmed their data. Nevertheless, analysis of the four remaining studies (8, 13, 15, 16) showed no significant heterogeneity (I 2 ¼ 0%), and the overall difference in DAS28 score decreased, but remained significantly different from zero (difference ¼ 0.53, 95% CI: 0.18, 0.88, P ¼ 0.0033). Five of the six studies, which reported DAS28 score also used this as the criterion to determine responsiveness to the TNF-a inhibitor. The OR for these studies was 0.23 (95% CI: 0.12-0.44).
Discussion
TNF-a inhibitors have revolutionized the treatment of RA. Although they have convincingly proven to be clinically efficacious in the treatment of RA, not all patients respond to these agents. This meta-analysis shows that the probability of successful treatment with anti-TNF-a agents is influenced, at least in part, by the À308 variant of the TNF-a gene possessed by the RA patient. Specifically, patients carrying the G/G genotype of À308 variant are more likely to respond to anti-TNF-a agents as compared with RA patients that are carriers of at least one A allele. The effect shown here seems to be present irrespective of the type of anti-TNF-a inhibitor (that is, receptor antagonist or monoclonal antibody).
The prevalence of the carrier status for the A allele is not infrequent. For the Caucasian population, among the seven studies in which participants were not selected on the basis of genotype at the À308 variant, 21 15 to 37% 9 of the RA patients were carriers of at least one A allele. Therefore, the clinical impact of prospective genotyping may be significant in the Caucasian RA patients. However, there may be a marked decrease in prevalence of the A carrier status among Asians, as only 1.4% of the Korean RA cohort were carriers of this allele. 12 It is of interest that in the Korean RA cohort, patients with the T allele of TNF-a À857 C/T SNP responded better to etancercept therapy than homozygotes of the C allele. 12 This finding has not been replicated in an independent Asian cohort, nor has it been thoroughly investigated in a Caucasian RA cohort. Therefore, the conclusions of this meta-analysis only pertain to a Caucasian RA population and cannot be generalized to an Asian RA cohort.
There are limitations in this meta-analysis. First, there is a scarcity of studies, which have investigated the relationship between the TNF-a À308 G/A polymorphism and responsiveness to TNF-a blockade therapy in moderate-to severe-RA. Second, those aforementioned studies have relatively small sample sizes limiting statistical power. Third, there is likely heterogeneity among the clinical profiles of the RA patients in the various studies. The differences include clinical parameters such as disease duration, disease activity at baseline, baseline functional scores and use of concomitant medication. Finally, two different outcome measures (DAS28 and ACR20) were used to assess the outcomes from anti-TNF therapy. As six of the nine studies reported the DAS28 score, this was the preferred response index used in this meta-analysis.
In using the DAS28 score, it would have been ideal if we could also report the percentage change in disease activity for all studies. However, these data were only available for a handful of studies. It is possible that even more discriminatory results would have been obtained between the A and non-A carrier status, if the disease activity score was used or if the response criteria were set at a higher threshold. For instance, in the study by Seitz et al., 14 14 of 17 patients carrying the A allele achieved a moderate response (as defined by DAS28 improvement of X1.2 and o2.2), whereas none had a good response (good response was defined as DAS28 improvement 42.2). In contrast, all 37 patients with the G/G genotype had a good response. Therefore, using a higher threshold for DAS28, instead of DAS28 X1.2 used in Figure 3 Forest plot of a random effects meta-analysis of six studies quantifying the decrease in DAS28 score after treatment with TNF-a inhibitors, by genotype at the TNF-a À308 variant. This analysis showed significant heterogeneity (I 2 ¼ 92.7%). The vertical line is at 0, corresponding to the null hypothesis of no difference in DAS28 decrease between RA patients carrying the A allele and RA patients with the G/G genotype. CI, confidence interval; RA, rheumatoid arthritis; TNF-a, tumor necrosis factor-a.
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this study, would have produced a greater difference of the response rate among the genotypes.
It is possible that a poor therapeutic response among carriers of the A allele of the À308 TNF-a gene variant is not specific to anti-TNF-a agents, but merely reflects more aggressive disease and/or poorer response to any therapeutic regime. The minor allele 'A' of the À308 variant has been earlier associated with disease susceptibility and severity. However, there are conflicting reports of the association between the A allele of TNF-a À308 gene and RA susceptibility as well as radiographic damage as summarized earlier by Kooloos et al. 19 This possibility will need to be explored further by examining the association of À308 genotypes with other therapeutic modalities in RA. However, whether À308 TNF-a genotypes are specific for anti-TNF-a agents does not necessarily diminish the potential clinical impact of this knowledge. Such crucial pharmacogenetic information may provide a superior therapeutic strategy, as therapies can be guided by the presence or absence of the À308 A allele.
On the basis of the high prevalence of the A carrier status for the À308 TNF-a variant and the consistent difference in response among carriers and non-carriers of the A allele, we feel that the utility of prospectively genotyping for the À308 variant before initiation of anti-TNF-a therapy should be evaluated. The value of this genotypic information will increase if there is further improvement in the response to anti-TNF-a agents based on the knowledge of the carrier status of the A allele. It is conceivable that those with the A allele could either be treated more aggressively with concomitant disease-modifying anti-rheumatoid drugs or implement these biologics earlier in the therapeutic regimen. Another potential option may include initiation of biologics that do not specifically target TNF-a blockade such as co-stimulatory antagonists (for example, abatacept) or anti-B cell therapy (for example, rituximab). Meanwhile, for those with the G/G genotype, it may be of interest to monitor therapeutic endpoints with anti-TNF-a monotherapy (if deemed appropriate on the basis of the type of anti-TNF therapy) rather than the more conventional combination therapy (use of anti-TNF-a agents and concomitant disease-modifying anti-rheumatoid drugs), which is routinely prescribed for the treatment of RA. At present, these therapeutic options are just hypotheses that will require testing in the clinical setting. However, there seems to be mounting evidence to proceed in formally evaluating these therapeutic approaches, as they may lead to improved effectiveness of these expensive drugs.
Materials and Methods
Data extraction: selection of association studies for analysis We searched MEDLINE citation index (from 1950 to July 2008), EMBASE (from 1980 to July 2008), as well as abstracts in major rheumatology journals (Arthritis Rheumatism, Annals of Rheumatic Disease, Rheumatology and Journal of Rheumatology). In searching the databases, the key words used in the search were 'tumor necrosis factor', 'TNF-alpha', 'TNF-alpha blockade', 'anti-TNF-a therapy', 'infliximab', 'etanercept', 'adalimumab', 'rheumatoid arthritis', 'TNF-a promoter SNPs' and 'TNF-a variant À308'. The key words were entered as both medical subject and text words. The language of origin was not limited. Once these articles were identified, the references of these articles were subsequently searched.
Genetic association studies that assessed TNF-a promoter variant À308 in RA were eligible for inclusion if: (1) the study was published by July 2008; (2) the study was original data that was not earlier published and (3) enough raw data was provided in the paper to calculate the OR. Studies that had overlapping data and/or insufficient data on the alleles that predicted response were excluded from statistical analysis.
The information was extracted from each study by two independent investigators (DO and NR). The results were subsequently reassessed by a third investigator after the relevant data was extracted (PR), and a consensus was reached for all studies. The information extracted included the authors, population, ethnicity, variant of TNF-a variant typed, year of publication, diagnosis of RA, duration of follow-up and response criteria (both DAS28 and ACR20 responses were recorded). Quality assessments were not done before data analysis, as relevant and well-established quality assessments tools were lacking for genetic association studies.
Statistical evaluation
As the homozygous A/A genotype was rare in all studies, patients with this genotype were pooled with patients with the G/A genotype, and the response of patients with the G/ G genotype was compared with the response of patients carrying an A allele. The OR was used to quantify the effect of the polymorphism on response. We applied a continuity correction of 0.5 to all four cells of the 2-by-2 contingency table for studies in which at least one of the groups had no events, so that estimates of OR and accompanying standard errors can be computed.
As we anticipated heterogeneity between studies, a random effect model was used to combine the ORs across studies. 20 This model can incorporate heterogeneity of effects between study results, when it exists. When the random variance component is estimated to be zero, the model reduces to a fixed effects model. Consistent with common practice, we have also carried out a statistical test for heterogeneity using the Cochran Q test 21 and quantified the degree of heterogeneity with the I 2 statistic. The I 2 statistic ranges from 0 to 100% and measures the degree of inconsistency across studies in a meta-analysis. 22 Higgins et al. 22 assign as low, moderate, and high to I 2 values of 25%, 50%, and 75%, respectively. Meta-analyzed ORs are reported with 95% CI as well as P-values for overall association.
Publication bias, which occurs when small studies are published only if the results are positive, was examined using a funnel plot. This plot is a graph with the effect size TNF-a À308 G/A variant and anti-TNF-a agents D D O'Rielly et al (OR) on the x axis and the inverse of variance of the effect on the y axis. Asymmetry without studies in the bottom left corner suggests publication bias. 23 The metaanalysis was implemented using the rmeta package (version 1.4) of the statistical package R (version 2.7.0, http://www. r-project.org/).
